Aceragen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 26
- Market Cap
- -
- Website
- http://www.aceragen.com
- Introduction
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
Phase 2
Withdrawn
- Conditions
- Cystic FibrosisCystic Fibrosis Pulmonary Exacerbation
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Aceragen
- Registration Number
- NCT05641298
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸New York Medical College, Hawthorne, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath